Pomerantz Law Firm Investigates HCA Healthcare Following Reduced Profit Guidance
Pomerantz LLP has launched an investigation into HCA Healthcare, Inc. (HCA) to determine if the company or its executives engaged in securities fraud or unlawful business practices. The probe follows a significant downward revision of the company's full-year 2026 profit guidance. The investigation stems from HCA's July 14, 2026, announcement regarding preliminary second-quarter results. The company reported that an unfavorable shift in its payer mix resulted in a revenue impact of approximately $400 million for the quarter. Following this disclosure, HCA shares dropped by 6.95%, falling $27.14 to close at $363.60.
Tickers: $HCA
Topics: class action lawsuit earnings guidance revision investor protection securities fraud investigation